X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effect. It is being evaluated for the treatment of schizophrenia.
Lead Product(s): AF710B
Therapeutic Area: Psychiatry/Psychology Product Name: AF710B
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effect. It is being evaluated in phase 1 clinical trials for the treatment of schizophrenia.
Lead Product(s): AF710B
Therapeutic Area: Neurology Product Name: ANAVEX 3-71
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
ANAVEX 2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is under phase 3 clinical development for the treatment of patients with Rett syndrome (RTT).
Lead Product(s): Blarcamesine
Therapeutic Area: Genetic Disease Product Name: Anavex 2-73
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
ANAVEX 2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is under phase 3 clinical development for the treatment of patients with Rett syndrome (RTT).
Lead Product(s): Blarcamesine
Therapeutic Area: Genetic Disease Product Name: Anavex 2-73
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
ANAVEX 2-73 (blarcamesine) is M1 & σ1 receptor agonist, which is being evaluated in phase 2/3 clinical trials for the treatment of Alzheimer’s Disease.
Lead Product(s): Blarcamesine
Therapeutic Area: Neurology Product Name: ANAVEX 2-73
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
ANAVEX2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is under phase 2/3 clinical development for the treatment of Alzheimer's disease.
Lead Product(s): Blarcamesine
Therapeutic Area: Neurology Product Name: ANAVEX2-73
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is being investigated for alzheimer’s disease.
Lead Product(s): Blarcamesine
Therapeutic Area: Neurology Product Name: Anavex 2-73
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is being investigated for rett syndrome.
Lead Product(s): Blarcamesine
Therapeutic Area: Genetic Disease Product Name: Anavex 2-73
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is being investigated for rett syndrome.
Lead Product(s): Blarcamesine
Therapeutic Area: Genetic Disease Product Name: Anavex 2-73
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. It is being investigated for rett syndrome.
Lead Product(s): Blarcamesine
Therapeutic Area: Genetic Disease Product Name: Anavex 2-73
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
